SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?

被引：0
作者：
Heinzelmann-Schwarz, V. [1 ]
Knipprath-Meszaros, A. M. [1 ]
Francis, J. [2 ]
Stadlmann, S. [3 ]
Vigo, F. [1 ]
Schoetzau, A. [2 ]
Singer, G. [3 ]
Vetter, M. [1 ]
机构：
[1] Univ Hosp Basel, Gynecol Canc Ctr, Basel, Switzerland
[2] Ovarian Canc Res Ctr, Dept Biomed, Basel, Switzerland
[3] Cantonal Hosp Baden, Inst Pathol, Baden, Switzerland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2017年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO7-0583
引用
收藏
页码：307 / 307
页数：1
相关论文
共 50 条
  • [21] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Cai, Yan
    Shu, Tong
    Zheng, Hong
    [J]. BMC WOMENS HEALTH, 2024, 24 (01)
  • [22] Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment
    Bay, Marie L.
    Skorda, Aikaterini
    Rasmussen, Benita S.
    Arias, Jaume R.
    Lauridsen, Anna R.
    Huhtinen, Kaisa
    Hautaniemi, Sampsa
    Hynninen, Johanna
    Kallunki, Tuula
    [J]. CANCER RESEARCH, 2024, 84 (05)
  • [23] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    [J]. CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [24] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
  • [25] Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer
    Cybulska, P.
    Spirtos, A.
    Filippova, O. T.
    Leitao, M. M., Jr.
    Sonoda, Y.
    Mueller, J. J.
    Gardner, G. J.
    Zivanovic, O.
    Hayes, S. A.
    Roche, K. Long
    Chi, D. S.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 281 - 282
  • [26] Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer
    Cybulska, Paulina
    Hayes, Sara A.
    Spirtos, Alexandra
    Rafizadeh, Michael J.
    Filippova, Olga T.
    Leitao, Mario
    Zivanovic, Oliver
    Sonoda, Yukio
    Mueller, Jennifer
    Lakhman, Yuliya
    Long, Kara
    Chi, Dennis S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1377 - 1380
  • [27] The Role of the STIC-Lesion in Patients with high-grade serous Ovarian Cancer
    Holly, J.
    du Bois, A.
    Harter, P.
    Schwameis, R.
    Schneider, S.
    Heikaus, S.
    Concin, N.
    Heitz, F.
    Traut, A.
    Ataseven, B.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E25 - E25
  • [28] Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
    Vetter, Marcus
    Stadlmann, Sylvia
    Bischof, Evelyne
    Margarint, Elena Laura Georgescu
    Schotzau, Andreas
    Singer, Gad
    Heinzelmann-Schwarz, Viola
    Montavon, Celine
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [29] Principles of dormancy evident in high-grade serous ovarian cancer
    Trevor G. Shepherd
    Frederick A. Dick
    [J]. Cell Division, 17
  • [30] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    [J]. JOURNAL OF PATHOLOGY, 2012, 227 (02) : 136 - 145
12345